Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Non-Current Assets (2020 - 2025)

Rani Therapeutics Holdings has reported Non-Current Assets over the past 6 years, most recently at $5.3 million for Q4 2025.

  • Quarterly results put Non-Current Assets at $5.3 million for Q4 2025, down 23.08% from a year ago — trailing twelve months through Dec 2025 was $22.7 million (down 45.91% YoY), and the annual figure for FY2025 was $5.3 million, down 23.08%.
  • Non-Current Assets for Q4 2025 was $5.3 million at Rani Therapeutics Holdings, up from $5.2 million in the prior quarter.
  • Over the last five years, Non-Current Assets for RANI hit a ceiling of $12.1 million in Q1 2024 and a floor of $4.6 million in Q3 2021.
  • Median Non-Current Assets over the past 5 years was $7.1 million (2023), compared with a mean of $7.2 million.
  • Biggest five-year swings in Non-Current Assets: soared 63.91% in 2024 and later plummeted 53.59% in 2025.
  • Rani Therapeutics Holdings' Non-Current Assets stood at $4.6 million in 2021, then soared by 54.01% to $7.1 million in 2022, then dropped by 0.48% to $7.1 million in 2023, then fell by 2.53% to $6.9 million in 2024, then fell by 23.08% to $5.3 million in 2025.
  • The last three reported values for Non-Current Assets were $5.3 million (Q4 2025), $5.2 million (Q3 2025), and $5.8 million (Q2 2025) per Business Quant data.